Cancer Nanomedicine Market & Pipeline Insight 2015

Description: During the last decade, there has been significant impact of the emergence of nanotechnology on clinical therapeutics. The pharmaceutical industry has witnessed advances in biocompatible nanoscale drug carriers in the form of liposomes and polymeric nanoparticles which have the potential to deliver numerous drugs with more efficiency and safety. The advantages of nanoparticle drug delivery, specifically, at the systemic level, include longer circulation half-lives, improved pharmacokinetics and reduced side effects which are major reasons for its increasing popularity. In the field of cancer therapy, the nanoparticles could possibly depend heavily on the enhanced permeability and retention effect which is caused by leaky tumor vasculatures for better drug accumulation at the tumor sites. Owing to such benefits, the therapeutic nanoparticles as a form of drug delivery has become a very promising field and has the potential to successfully replace traditional chemotherapy.

Scientists and engineers have been specifically researching on discovering different approaches to deliver multiple therapeutic agents using a single drug nanocarrier. Given the fact that application of multiple drugs could possibly suppress the notorious phenomenon of cancer chemo-resistance, these efforts have been motivated to a great extent. It has been observed that the cancer cells tend to exhibit a diminishing response over the course of a chemo-treatment because they acquire defense mechanisms by over expressing drug efflux pumps, increasing drug metabolism, enhancing self-repairing ability or expressing altered drug targets. In order to reduce the cancer drug resistance for better therapeutic effectiveness, the “combination chemotherapy” has been adopted for a long time in the clinics as a primary cancer treatment regimen.

While on the one hand, applying multiple drugs with different molecular targets could possibly raise the genetic barriers needed to be overcome for cancer cell mutations, thereby delaying the cancer adaptation process. On the other hand, it has been proved that multiple drugs targeting the same cellular pathways could sometimes function synergistically for higher therapeutic efficacy and higher target selectivity. However, there are many shortcomings in the current combination chemotherapies. These include varying pharmacokinetics, biodistributions and membrane transport properties among different drug molecules which tend to make dosing and scheduling optimization extremely difficult. These challenges have made the researchers and clinicians to investigate more efficient approaches to incorporating nanotechnology with combination chemotherapy.

The future years are expected to be bright with regards to the development of nanoparticle drug delivery systems for cancer treatment. The identification of nanoparticle materials which are relatively safe and effective in delivering therapeutic agents to the target tumor sites is the need of the hour. The protein polymers from natural sources are considered to be promising materials for constructing the nanocarrier systems. With the commercial success of albumin-based nanoparticles, there has been significant amount of interest in other proteins also. By rationally designing protein nanoparticles based on their behaviors in the tumor microenvironment and based on cancer cell biology, improved efficacy and safety of cancer therapy can be achieved.

“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight

- Nanomedicine for Cancer Therapies
- Cancer Nanoparticles Drug Delivery Systems Classification
- Mechanism of Cancer Nanomedicine Therapy
- Cancer Nanomedicine Clinical Pipeline Overview
- Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
- Cancer Nanomedicine Clinical Pipeline: 79 Drugs
- Marketed Cancer Nanomedicine: 8 Drugs

Contents:

1. Introduction to Nanomedicine
2. Nanomedicine for Cancer Therapies
3. Need for Nanomedicine in Cancer Therapy

4. Cancer Nanoparticles Drug Delivery Systems Classification

5. Mechanism of Cancer Nanomedicine Therapy

6. Global Cancer Nanomedicine Market Outlook
   6.1 Current Market Scenario
   6.2 Cancer Nanomedicine Clinical Pipeline Overview

7. Global Cancer Nanomedicine Market Dynamics
   7.1 Favorable Market Parameters
   7.2 Commercialization Challenges

8. Global Cancer Nanomedicine Market Future Prospects

9. Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
   9.1 Research
   9.2 Preclinical
   9.3 Phase-I
   9.4 Phase-I/II
   9.5 Phase-II
   9.6 Phase-II/III
   9.7 Phase-III

10. Marketed Cancer Nanomedicine by Company & Indication

11. Suspended & No Development Reported in Cancer Nanomedicine Clinical Pipeline
   11.1 No Development Reported
   11.2 Discontinued

12. Competitive Landscape
   12.1 Abraxis BioScience
   12.2 Access Pharmaceuticals
   12.3 Alnylam Pharmaceuticals
   12.4 Arrowhead Research
   12.5 BIND Biosciences
   12.6 Epeius Biotechnologies
   12.7 Nanobiotix
   12.8 NanoCarrier
   12.9 Nippon Kayaku
   12.10 Samyang
   12.11 Takeda Pharmaceutical

List of Figures:

Figure 1-1: Introduction to Nanomedicine
Figure 1-2: Applications Areas of Nanomedicine
Figure 2-1: Technology Evolution of Targeted Drug Delivery using Nanoparticles for Cancer Treatment
Figure 3-1: Need & Importance of Nano Drug Delivery for Cancer
Figure 4-1: Types of Nanoparticles Drug Delivery Systems
Figure 5-1: Mechanism of Cancer Nanomedicine Therapy
Figure 5-2: Multiblock Polymer Nanoparticles Attacks Tumors- Step by Step Process of Drug Delivery
Figure 6-1: Novel Drug Delivery Systems for Cancer
Figure 6-2: Cancer Nanomedicine Pipeline by Phase (%), 2015
Figure 6-3: Cancer Nanomedicine Pipeline by Phase (Number), 2015
Figure 6-4: No Development Reported in Cancer Nanomedicine Pipeline by Phase (%), 2015
Figure 6-5: No Development Reported in Cancer Nanomedicine Pipeline by Phase (Number), 2015
Figure 6-6: Discontinued Cancer Nanomedicine Pipeline by Phase (%), 2015
Figure 6-7: Discontinued Cancer Nanomedicine Clinical Pipeline by Phase (Number), 2015
Figure 12-1: Arrowhead Research Corporation Clinical Pipeline
Figure 12-2: NanoCarrier Clinical Pipeline
List of Tables:

Table 4.1: Liposomes for Combination Cancer Therapy
Table 4.2: Polymeric nanoparticles & Polymer Drug Conjugates for Combination Cancer Therapy
Table 4.3: Dendrimers & other Nanoparticles for Combination Cancer Therapy

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3101003/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cancer Nanomedicine Market & Pipeline Insight 2015
Web Address: http://www.researchandmarkets.com/reports/3101003/
Office Code: SCH32TCP

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>USD 2400 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>USD 3000 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp